{"id":6398,"date":"2021-03-10T21:43:58","date_gmt":"2021-03-11T05:43:58","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6398"},"modified":"2021-03-10T21:43:58","modified_gmt":"2021-03-11T05:43:58","slug":"extremely-potent-human-monoclonal-antibodies-from-covid-19-convalescent-patients","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/10\/extremely-potent-human-monoclonal-antibodies-from-covid-19-convalescent-patients\/","title":{"rendered":"Extremely Potent Human Monoclonal Antibodies from COVID-19 Convalescent Patients"},"content":{"rendered":"<ul>\n<li>A study that identified highly potent human monoclonal antibodies (mAbs) found that the most potent mAbs recognized the SARS-CoV-2 spike protein receptor-binding domain, followed by those that recognized the S1 domain, the spike protein trimer, and the S2 subunit. Only 1.4% neutralized the virus with a potency of 1\u201310\u00a0ng\/mL. The authors also engineered the most potent mAb (J08) to have an enhanced half-life and reduced risk of antibody-dependent enhancement, which neutralized wild-type virus and emerging variants containing D614G, E484K, and N501Y substitutions. <span class=\"Apple-converted-space\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i>Andreano et al.\u00a0(Feb 23, 2021). Extremely Potent Human Monoclonal Antibodies from COVID-19 Convalescent Patients. Cell. <\/i><a href=\"https:\/\/doi.org\/10.1016\/j.cell.2021.02.035\">https:\/\/doi.org\/10.1016\/j.cell.2021.02.035<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A study that identified highly potent human monoclonal antibodies (mAbs) found that the most potent mAbs recognized the SARS-CoV-2 spike protein receptor-binding domain, followed by those that recognized the S1 domain, the spike protein trimer, and the S2 subunit. Only 1.4% neutralized the virus with a potency of 1\u201310\u00a0ng\/mL. The authors also engineered the most&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/10\/extremely-potent-human-monoclonal-antibodies-from-covid-19-convalescent-patients\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-6398","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6398"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6398\/revisions"}],"predecessor-version":[{"id":6399,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6398\/revisions\/6399"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6398"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}